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cAMP/PKA pathwayA critical role for mitochondrial dysfunction has been proposed in the pathogenesis of Down's syndrome (DS),
a humanmultifactorial disorder caused by trisomy of chromosome 21, associated withmental retardation and
early neurodegeneration. Previous studies from our group demonstrated in DS cells a decreased capacity of
the mitochondrial ATP production system and overproduction of reactive oxygen species (ROS) in mitochon-
dria. In this study we have tested the potential of epigallocatechin-3-gallate (EGCG) – a natural polyphenol
component of green tea – to counteract the mitochondrial energy deﬁcit found in DS cells. We found that
EGCG, incubatedwith cultured lymphoblasts and ﬁbroblasts fromDS subjects, rescuedmitochondrial complex
I and ATP synthase catalytic activities, restored oxidative phosphorylation efﬁciency and counteracted oxida-
tive stress. These effects were associated with EGCG-induced promotion of PKA activity, related to increased
cellular levels of cAMP and PKA-dependent phosphorylation of the NDUFS4 subunit of complex I. In addition,
EGCG strongly promoted mitochondrial biogenesis in DS cells, as associated with increase in Sirt1-dependent
PGC-1α deacetylation, NRF-1 and T-FAM protein levels and mitochondrial DNA content.
In conclusion, this study shows that EGCG is a promoting effector of oxidative phosphorylation and mito-
chondrial biogenesis in DS cells, acting through modulation of the cAMP/PKA- and sirtuin-dependent path-
ways. EGCG treatment promises thus to be a therapeutic approach to counteract mitochondrial energy
deﬁcit and oxidative stress in DS.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Down's syndrome (DS) is a genetic disorder caused by trisomy of
chromosome 21. Individuals with DS show an early aging associated
with a decline in intellectual abilities, with a high tendency to devel-
op neuropathological features associated with Alzheimer's disease
[1,2]. As in several genetic disorders characterized by propensity to
premature aging, oxidative stress is a phenotypic hallmark also in
DS [3]. Although the molecular mechanisms involved in DS are largely; DCF, dichloroﬂuorescein; DS,
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l rights reserved.unknown, several studies in different animal models [2,4,5] as well as
in humans [6,7], have revealed that mitochondrial dysfunction is crit-
ically associated with DS pathogenesis. The role of mitochondrial dys-
function in the composite cellular and molecular events leading to
neurodegeneration and intellectual deﬁciency occurring in DS re-
mains, however, to be clariﬁed. A deﬁcit in the system of mitochon-
drial energy production, due to the impairment of mitochondrial
respiratory chain complex I, ATP synthase, ADP/ATP translocator
and adenylate kinase activities, was recently found by our group in ﬁ-
broblasts from DS subjects [8,9]. These alterations were associated
with perturbation in post-translational cAMP/PKA-mediated process-
es, as well as with exceeding oxidative stress in DS [8,9]. Attempts to
improve mitochondrial function and/or mass can be an attractive
strategy to correct DS-associated clinical phenotypes which are
linked to increased oxidative stress and energy deﬁcit. In this respect,
mitochondrial functions and dynamics are increasingly recognized
as a major factor in supporting neurogenesis and in preventing
neurodegeneration [10]. Although recent studies indicated that
mitochondrial-targetedmolecules, such as coenzyme Q(10), provide
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tervention trials using standard antioxidant supplements have failed
to produce uniform therapeutic effects [11].
In this study we tested the capability of epigallocatechin-3-gallate
(EGCG) – a member of a natural polyphenol family, found in great
amount in green tea leaves – to restore mitochondrial energy deﬁcit
and counteract oxidative stress in DS cells. EGCG, which has been
extensively studied for its anticarcinogenic (for Refs. see [12]) and
anti-inﬂammatory [13] effects, is a mitochondrial-targeted molecule
displaying a selective antiapoptotic effect against inducers of mitochon-
drial oxidative stress in a variety of neuronal cell types [14]. EGCG has
been found to prevent mitochondrial deterioration in aged rat brain
[15], reduce cerebral amyloidosis [16] and correct amyloid-induced mi-
tochondrial dysfunction in a transgenicmicemodel of Alzheimer disease
[17]. Although many modalities of action have been recently suggested
for this catechine (reviewed in [18]), themolecularmechanism underly-
ing its effects on mitochondria remains poorly understood. It has been
reported that EGCG modulates key regulators of mitochondrial metabo-
lism such as Sirt1 activity [19] and cAMP levels [20,21]. What makes
ECGC an interesting candidate drug in DS treatment is also its activity
as speciﬁc and safe inhibitor of the chromosome 21 encoded DYRK1A
[22], a kinase protein involved in brain development and in the control
of synaptic plasticity [23]; EGCG was found to rescue brain defect in-
duced by DYRK1A overexpression [24].
The results of the present work show that EGCG rescues mito-
chondrial energy impairment, prevents overproduction of reactive
oxygen species (ROS) and peroxidation of lipid membranes and in-
creases mitochondrial biogenesis in cultured lymphoblasts and ﬁbro-
blasts from DS patients.2. Materials and methods
2.1. Cell cultures and materials
Five normal and six DS human phenotypically characterized fetal
skin ﬁbroblast cell lines, established from fetuses spontaneously
aborted at a gestational age between 14 and 18 weeks, were obtained
from the Galliera Genetic Bank, member of Telethon genetic Biobank
Network. The Galliera Genetic Bank operates in agreement with ethical
guidelines stated in the TGB Network Charter with informed consent
obtained from the guardians. The ﬁbroblast cell lines were cultured at
37 °C in humidiﬁed 5% CO2/95% air in RPMI 1640 medium (GIBCO/
BRL) supplemented with 15% heat-inactivated fetal bovine serum
(GIBCO/BRL), 2 mM L-glutamine, penicillin (100 units/ml) and strepto-
mycin (100 μg/ml) (GIBCO/BRL). Adherent ﬁbroblasts were subjected
to a 1:2 split every 6 days. In the experiments a comparable number
of culture passages (5–15) were used. At these passages the growth
rate of DS ﬁbroblasts was comparable with that of normal cells since
the cell energy status did not signiﬁcantly change in DS as compared
with normal cells [8].
Epstein–Barr virus-immortalized lymphoblastoid cells lines,
established from six children age ranging from 3 to 10 years,
phenotypically characterized as DS, and ﬁve age-matched con-
trols were provided by the Department of Pediatrics, Federico II
University of Naples with informed consent obtained from the
patients and their guardians. Floating lymphoblastoid cell lines
were grown in RPMI 1640 medium supplemented with 20% fetal
bovine serum, 2 mM L-glutamine, 200 units/ml penicillin, 200 μg/ml
streptomycin and 160 mg/l gentamicin sulfate (GIBCO/BRL) at 37 °C
in humidiﬁed 5% CO2/95% air. Cells were subjected to a 1:2 split every
4 days.
Protein concentration was quantiﬁed by using the modiﬁed Bradford
assay (BIO-RAD protein assay) from Bio-RAD according to the manufac-
turer's instructions. All reagents used were from Sigma-Aldrich unless
otherwise speciﬁed.2.2. EGCG treatment
EGCG – extract from green tea leaves with a purity>95%
(Sigma-Aldrich) – was freshly prepared for each experiment at
20 mM concentration in PBS. Fibroblasts (once they reached 70%
conﬂuence) and lymphoblastoid cells (2–4×106 cells in 10–20 ml
of culture media) were both treated with 20 μM EGCG added to the
culture medium for 24 h. Since it has been demonstrated that in cul-
ture condition EGCG could induce apoptosis and produce itself ROS
in a dose-dependent manner [25], dose- and time–response studies
were performed to verify that the treatment with 20 μM EGCG did
not affect viability of both control and DS cells and did not induce re-
lease of hydrogen peroxide (H2O2) in the culture medium (see
Supplementary Fig. S1). For time-dependent experiments, the incu-
bation medium containing EGCG was changed every 24 h and fresh-
ly prepared EGCG was added for 72 h-time period.
2.3. Measurement of mitochondrial ATP production rate
The rate of ATP production by oxidative phosphorylation was
determined in digitonin-permeabilized cells, essentially as previously
described [8]. Brieﬂy, aliquots of trypsinized ﬁbroblasts or ﬂoating
lymphoblastoid cells (0.5 mgprotein),washedwith PBS,were incubated
at 37 °C in 2 ml of respiratory medium consisting of 210 mMmannitol,
70 mM sucrose, 20 mM Tris/HCl, 5 mM KH2PO4/K2HPO4, (pH 7.4),
3 mM MgCl2 in the presence of the ATP detecting system (ATP-ds)
consisting of glucose (2.5 mM), hexokinase (HK) (2 e.u.), glucose
6-phosphate dehydrogenase (G6P-DH) (1 e.u.) and NADP+ (0.25 mM)
in the presence of rotenone (3 μM) and succinate (5 mM) as energy
source, plus 10 μM diadenosine pentaphosphate (Ap5A), used to specif-
ically inhibit adenylate kinase [26]. After 5 min of incubation with 0.01%
digitonin, the reduction of NADP+ in the extramitochondrial phase,
which reveals ATP formation from externally added ADP (0.5 mM),
was monitored as an increase in absorbance at 340 nm. Care was taken
to use enough HK/G6P-DH coupled enzymes to ensure a non-limiting
ADP-regenerating system for the measurement of ATP production.
2.4. Measurement of cellular ATP content
Fibroblasts were detached from plate by trypsin treatment, washed
with PBS and cellular ATPwas extracted by using the boilingwater pro-
cedure as described in [27]. The amount of intracellular ATP was deter-
mined enzymatically in the extracts as described in [8].
2.5. Measurement of mitochondrial complex I and complex V activities
Measurements of complex I and complexV activitieswere carried out
in mitochondrial membrane-enriched fractions from both cultured ﬁ-
broblast and lymphoblastoid cells. Aliquots of trypsinized ﬁbroblasts or
ﬂoating lymphoblastoid cells were washed with ice-cold PBS, frozen in
liquid nitrogen and kept at−80 °C until use. For isolation of mitochon-
drial membrane-enriched fractions, the cell pellets were thawed at 2–
4 °C, suspended in 1 ml of 10 mM Tris–HCl (pH 7.5), supplemented
with 1 mg/ml BSA, and exposed to ultrasound energy for 15 s at 0 °C.
The ultrasound-treated cells were centrifuged (10 min at 600 g, 4 °C).
The supernatant was collected and centrifuged again (10 min at
14,000 g, 4 °C) to obtain a mitochondrial pellet that was suspended in
0.1 ml of the respiratorymedium. The activity of NADH:ubiquinone ox-
idoreductase (complex I) and ATPase-dependent ATP hydrolase (com-
plex V) was measured in the same assay with sequential addition of
reagents, essentially as described in [28].
2.6. ROS detection
ROSwere visualized in live ﬁbroblasts by using laser scanning con-
focal microscopy imaging. Cells were cultured at low density on
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20 min at 37 °C with 3 μMMitoSOX™ (Molecular Probes), a selective
mitochondria-targeted probe speciﬁc for superoxide anion [29]. After
washing with PBS, stained cells were examined under a Leica TCS SP5
II microscope (images collected using a 60× objective). The red ﬂuo-
rescence of MitoSOX was analyzed by exciting the sample with a
HeNe laser 543 (λex 543 nm).
Quantitative analysis of intracellular ROSwas performed bymeans of
an LS50 Perkin Elmer spectroﬂuorimeter using 2′,7′-dichloroﬂuorescein
diacetate (DCFH-DA), a non-ﬂuorescent dyewhich is hydrolyzed in cells
and reacts with multiple types of ROS, mainly H2O2, to give the ﬂuores-
cent product, dichloroﬂuorescein (DCF) [30]. Cultured cells were incu-
bated with 5 μM DCFH-DA for 30 min in growth conditions, washed
and suspended in PBS. Fluorescence emission was recorded at λex
488 nm and λem 520 nm and normalized to the protein content to de-
termine the relative ROS production.
To measure the pro-oxidant dose–response of EGCG, 1 h after the
treatment with different concentrations of EGCG, culture media were
collected and the amount of H2O2 in the culture medium was ana-
lyzed using Amplex® Red Hydrogen Peroxide/Peroxidase Assay kit
(Molecular Probes) (see Supplementary Fig. S1).
2.7. Assessment of lipid peroxidation
Cis-parinaric acid ﬂuorescence was used to determine the chemi-
cal process of lipid peroxidation of membranes. Cis-parinaric acid, a
fatty acid that contains 4 conjugated double bonds that render it nat-
urally ﬂuorescent, is attacked during lipid peroxidation reactions.
Accordingly, cis-parinaric acid ﬂuorescence is quenched in lipid peroxi-
dation reactions [31]. Fibroblasts (100 μg protein) were suspended into
2 mL of PBS that contained cis-parinaric acid (5 μM;Molecular Probes),
and incubated in darkness at 37 °C for 30 min. Afterward, ﬂuorescence
at λex 318 nm and λem 410 nm was recorded and normalized to the
protein content to determine the chemical process of lipid peroxidation.
Themore lipid peroxidation that occurs, the less ﬂuorescence is detected.
2.8. Measurement of MnSOD and Cu/ZnSOD activity
MnSOD and Cu/ZnSOD activities were determined by using a native-
gel activity-stain [32]. Lymphoblastoid cells were collected by centrifu-
gation and resuspended in PBS in the presence of the protease inhibitor
phenylmethanesulfonylﬂuoride (PMSF). Total cellular protein extracts
were prepared by sonicating cell suspensions on ice. Equal amounts of
protein were separated by native gel-electrophoresis, and SOD activity
assayed by incubating the gel with nitroblue tetrazolium. MnSOD was
distinguished from cyanide-sensitive Cu/ZnSOD, by the addition of
2 mM cyanide. Band intensity relative to the in situ activity staining
gels was calculated densitometrically using Quantity One-4.4.1 imaging
software (Bio-Rad Laboratories). Immunoblot analysis of the same sam-
ples with antibody against actin was used to verify equal loading.
2.9. Measurements of cellular cAMP levels and PKA activity
Cellular cAMP levels were measured in cell extracts with cAMP
ELISA Kit from Stressgen, following the manufacturer's instructions.
The activity of PKA was measured in cell extracts with the
cAMP-dependent PKA Assay System (Stressgen), as recommended by
the manufacturer.
2.10. Immunoblot analysis
Cells were lysed with 0.1% Triton in PBS in the presence of a pro-
tease inhibitor cocktail (Sigma-Aldrich). Cell lysate (0.05 mg protein)
was resolved by a 10%–12% SDS-polyacrylamide gel (depending on
the molecular weight) and transferred to a polyvinylidene diﬂuoride
membrane (Millipore). Membranes were blocked by TBS-T (50 mMTris, 150 mM NaCl, 0.02% Tween 20, pH 7.5) containing 5% non-fat
milk and probed with primary antibodies overnight at 4 °C (see Sup-
plementary Table 1). Immunoblot analysis was performed, essentially
as described in [33], using horseradish peroxidase-conjugated anti-
mouse or anti-rabbit antibodies and enhanced chemiluminescence
Western blotting reagents (Amersham, Pharmacia Biotech). Mem-
branes were also probed with anti-β-actin antibody as internal load-
ing control and densitometry value of immunoreactive bands for each
sample was normalized versus the corresponding densitometry value
of β-actin.
2.11. Quantitative analysis of mtDNA content
Total genomicDNAwas extracted fromnormal andDS cell lines using
the NucleoSpin kit (Macherey–Nagel) and quantitative real-time PCR re-
actions were performed by using the Applied Biosystems™ 7900HT and
the SYBR-Green PCR Master Mix (Qiagen). Primers for two mtDNA se-
quences, D-loop and cytochrome c oxidase II (COX II), and for the nuclear
DNA sequence of β-actin were used, as described in [8]. Triplicate reac-
tions were performed for each marker in a 96-well plate using a
two-step ampliﬁcation program consisting in an initial denaturation at
95 °C for 15 min, followed by 35 cycles of 94 °C for 20 s and 61 °C for
30 s. Standard curves were generated from each experimental plate
using a serial 5-fold dilutions of genomic DNA.
2.12. Immunoprecipitation of PGC-1α
Lymphoblastoid cells (0.5 mg protein) were sonicated and 350 μg of
proteinwas incubated for 12 h at 4 °C in 700 μl of RIPA buffer containing
150 mM NaCl, 5 mM EDTA, 50 mM Tris/HCl, 0.1% SDS, 1% Triton X-100,
pH 7.4, in the presence of 2 μg of antibody against PGC-1α (Millipore).
After 12 hour incubation, 40 mg of protein A-sepharose was added to
the mixture and the immunocomplex was pelleted by centrifugation
and washed with RIPA buffer supplemented with the protease inhibitor
cocktail. To remove the protein A-sepharose-antibody complex, the pel-
let was suspended in 100 mM glycine, pH 2.5 and then centrifuged at
600 ×g for 5 min at 4 °C. The supernatant containing the released
PGC-1α protein was ﬁnally collected, separated by SDS-PAGE, trans-
ferred to a nitrocellulose membrane and immunoblotted with antibody
against PGC-1α and Acetyl-Lysine.
2.13. Measurement of NAD+/NADH ratio
NAD+ and NADH levels were measured in untreated and EGCG-
treated cell extracts prepared from 1 to 3×106 cells by using NAD+/
NADH Assay Kit from Abcam, following the manufacturer's instructions.
After NADH developer addition, OD450 nm was read 1 h after incubation.
2.14. Transmission electron microscopy
24 h after EGCG treatment, DS and controlﬁbroblastswere collected
by centrifugation. Cell pelletswere thenwashed in PBS and ﬁxed as pre-
viously described [34]. Ultrathin sections were placed on Formvar
carbon-coated copper grids, stainedwith uranyl acetate and lead citrate
and observed under a Jeol 100 SX transmission electron microscope
(Jeol, Ltd, Japan). The number of total and RER-surrounded mitochon-
dria was quantiﬁed in 20 cells of similar size and nucleo/cytoplasm
ratio. Two independent samples were analyzed for both DS patients
and controls.
2.15. Statistical analysis
All data are expressed as mean±standard deviation (SD). Statisti-
cal evaluation of the differential analysis was performed by one way
ANOVA and Student's t-test. The threshold for statistical signiﬁcance
was set at Pb0.01.
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3.1. EGCG restores oxidative phosphorylation deﬁcit in human DS cells
In the light of our previous studies showing a deﬁcit of mitochon-
drial ATP synthase and complex I activities in DS cells, ascribed to de-
pression of post-translational cAMP/PKA-mediated phosphorylation
[8,9], and since EGCG is reported to be an inhibitor of phosphodiester-
ases [20] as well as an activator of adenylate cyclase [21], we investi-
gated whether EGCG was able to prevent mitochondrial energy
impairment in DS cells.
First we checked the optimal conditions for EGCG treatment (see
Supplementary Fig. S1) and found that exposure of both DS ﬁbroblast
and lymphoblastoid cells to 20 μM EGCG for 24 h, almost completely
restored the deﬁcit of mitochondrial ATPase (complex V) activity
(Fig. 1A and B) and completely prevented the decline of complex I
activity (Fig. 1C and D). No signiﬁcant difference in these activities
was found between untreated and EGCG-treated control cells (not
shown). EGCG concentrations lower than 20 μM did not completely
prevent this impairment and no changes in EGCG effects were ob-
served extending cell exposure to 20 μM EGCG for 72-h period (not
shown).
To investigate whether EGCG could improve energy production in
DS cells, we measured both ATP synthesized via mitochondrial oxida-
tive phosphorylation (OXPHOS) and the total cellular levels of ATP
(Fig. 2). Treatment of both ﬁbroblast and lymphoblastoid DS cells
with 20 μM EGCG for 24 h, signiﬁcantly prevented the impairment
of mitochondrial ATP synthesis (Fig. 2A and B). EGCG concentrations
lower than 20 μM were not fully effective in the prevention of mito-
chondrial energy impairment in DS cells (Fig. 2C). Consistent with aFig. 1. Effect of EGCG on complex I and V activities in DS ﬁbroblast and lymphoblastoid cells.
D) the activity of the complex I of the mitochondrial respiratory chain were measured spec
membrane-enriched fractions (0.1 mg protein) from ﬁbroblasts and lymphoblastoids. Data a
ﬁve CT samples from different subjects. Signiﬁcant differences between untreated and treacompensatory enhancement of glycolysis in DS cells [8], in a glucose
growth medium the cellular level of ATP was only slightly reduced
in DS compared with normal cells (Fig. 2D); conversely, ATP content
was drastically decreased when DS cells were grown in a galactose
medium in the absence of glucose, a condition in which ATP is essen-
tially produced by mitochondrial OXPHOS [8]. EGCG treatment con-
ferred to DS cells the capability to maintain ATP levels in a galactose
medium in the absence of glucose (Fig. 2D).3.2. Activation of cAMP/PKA pathway by EGCG
The possible involvement of cAMP/PKA pathway in the capability of
EGCG to restore complex I deﬁcit inDS cellswas then investigated.Mea-
surements of both cellular cAMP pool (Fig. 3A) and PKA activity
(Fig. 3B), as a function of EGCG incubation time, was analyzed in DS
cells. As in ﬁbroblasts [9], also in lymphoblastoid cells both cAMP
basal levels and PKA activitywere found lower inDS cell than in control.
6 h after incubation, both cAMP levels and PKA activity increased by
about 50% in EGCG-treated DS cells and both remained higher with re-
spect to untreated DS cells, although with a decreasing trend of cAMP
levels during incubation time. No signiﬁcant difference was found
between untreated and EGCG-treated control cells (not shown).
It has been reported that cAMP/PKA pathway activation in cell cul-
tures is associated with increase in the phosphorylation level of the
NDUFS4 complex I subunit and complex I activity [35,36]. Analysis
of the NDUFS4 phosphorylation level by a speciﬁc antibody for the
phosphorylated C-terminus of NDUFS4 protein showed a reduced
NDUFS4 phosphorylation level in DS cells with respect to normal
cells (Fig. 3C and D). 6 h-EGCG treatment promoted the expression(A and B) The activity of the ATPase-dependent ATP hydrolysis (complex V) and (C and
trophotometrically at 340 nm at 37 °C in 1 ml of respiratory medium in mitochondrial
re reported as the mean values (±S.E.) from three different experiments on six DS and
ted cells are indicated with asterisks (*=Pb0.01).
Fig. 2. Effect of EGCG on the rate of mitochondrial ATP synthesis and cellular ATP content in DS ﬁbroblast and lymphoblastoid cells. (A and B) The rate of mitochondrial ATP synthesis
wasmeasured spectrophotometrically at 340 nmat 37 °C in 2 ml of respiratorymedium in live digitonin-permeabilized control (CT) andDS (A) ﬁbroblast and (B) lymphoblastoid cells.Where
indicated, DS cells were incubated for 24 hwith 20 μMEGCG (DS+EGCG). (C) EGCG dose-dependence effect onmitochondrial ATP synthesis rate in ﬁbroblasts. (D) EGCG effect on the steady
state levels of ATP inDSﬁbroblasts. Cellswere cultured for 48 h in amediumwithout glucose and supplementedwith either 10 mMglucose (GLU) or 10 mMgalactose (GAL).Where indicated,
cellswere incubated for 24 hwith 20 μMEGCG. Cellular ATP contentwasmeasured as detailed in theMaterials andmethods section and reported as a percentage of that in control cells grown
in the presence of 10 mMglucose. Data are reported as themean values (±S.E.) from three different experiments on six DS and ﬁve CT samples. Signiﬁcant differences between untreated and
treated cells are indicated with asterisks (*=Pb0.01).
Fig. 3. EGCG modulates the cAMP/PKA signaling pathway. (A) Time-course measurement of cAMP cellular content and (B) PKA activity in cell lysate obtained from lymphoblastoid
cells. Normal (CT) and DS cells were incubated with 20 μM EGCG and measurements made at the time-period indicated. (C) Representative immunoblotting and (D) densitometric
analysis of protein level NDUFS4-complex I subunit (NDUFS4) and its phosphorylated form (P-NDUFS4) after 6 h of incubation with EGCC. The levels of NDUFS4 phosphorylation
are calculated as ratio of P-NDUFS4/NDUFS4; (E) complex I activity measured at 6 h incubation. Values are reported as the means (±S.E.) of three independent experiments
performed on ﬁve normal and six DS lymphoblastoid cell lines. Signiﬁcant differences between untreated and treated cells are indicated with asterisks (*=pb0.01).
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and rescued complex I activity (Fig. 3E).3.3. EGCG counteracts oxidative stress in human DS cells
To check the capability of EGCG to counteract oxidative stress, ROS
production and lipid peroxidation, as well as the activities of certain
antioxidant enzymes (MnSOD and Cu/ZnSOD), were measured in DS
cells (Fig. 4). 24 h treatment with 20 μM EGCG prevented superoxide
anion overproduction by mitochondria, as revealed by confocal mi-
croscopy analysis carried out in DS ﬁbroblasts by staining cells with
the mitochondrial probe MitoSOX (Fig. 4A). EGCG also prevented
the increase in H2O2 level in both DS ﬁbroblast and lymphoblastoid
cells, as observed by DCF ﬂuorescence measurements (Fig. 4B and C).
When lipid peroxidation was assessed, a greater loss of cis-parinaric
acid ﬂuorescence (i.e. a higher membrane lipid peroxidation) was
observed in DS ﬁbroblasts with respect to normal cells (Fig. 4D). Consis-
tent with the prevention of ROS accumulation by EGCG, lipid peroxida-
tion was completely abolished by EGCG treatment.
Unlike cis-parinaric acid ﬂuorescence, the activity of MnSOD and
Cu/ZnSOD both higher in DS cells – particularly Cu/ZnSOD encodedFig. 4. Control of oxidative stress in human DS cells by EGCG. (A) Imaging by confocal micro
above and stained with 3 μM MitoSOX while ﬂuorescence of MitoSOX was visualized in liv
confocal z-planes and represent typical examples. Bars, 50 μm. (B and C) Quantiﬁcation of
ﬂuorimetric analysis in (B) ﬁbroblasts and (C) lymphoblastoid cells. (D) Lipid peroxid
cis-parinaric acid ﬂuorescence arbitrary units (A.U.) measured by ﬂuorimetric analysis in ﬁ
chemical staining of a native-gel (E). Bar graph shows quantiﬁcation of SOD positive ba
Where indicated, control and DS cells were incubated for 24 h with 20 μM EGCG (CT+EGCG
performed in triplicate on ﬁve normal and six DS cell lines. Signiﬁcant differences betweenby chromosome 21 – did not disclose any change between untreated
and EGCG-treated cells (Fig. 4E and F).
3.4. EGCG promotes mitochondrial biogenesis in human DS cells
To test whether the EGCG promoting effect on the activity of com-
plexes I and V (see Fig. 2) was associated with changes in their content,
the levels of some OXPHOS complex subunits were analyzed. A shared
pattern of increase in the levels of subunits of all OXPHOS complexes
was observed in DS ﬁbroblasts and particularly in lymphoblastoid
cells upon treatment with EGCG (Fig. 5A).
To verify if the general increase in the amount of OXPHOS proteins,
found in DS cells treated with EGCG, was associated with an increased
mitochondrial biogenesis, mtDNA content in DS and EGCG-treated DS
cells compared with control cells was measured by real-time PCR. As
shown in Fig. 5B and C, mtDNA, already higher in DS cells than in con-
trol, further increased (about 3-fold) in DS cells upon EGCG treatment.
It can be noted that an increase of mtDNA content, albeit less extended
(1,5-fold), was also found in EGCG-treated control cells.
To verify if the increase of both mitochondrial proteins and mtDNA
promoted by EGCGwas the consequence of the activation of key factors
involved inmitochondrial biogenesis pathway, wemeasured in control,scopy of superoxide anion generation in DS ﬁbroblasts. Cells were treated as described
e ﬁbroblasts by laser scanning confocal microscopy. Images are superimpositions of 10
intracellular ROS was reported as DCF ﬂuorescence arbitrary units (A.U.) measured by
ation analysis in ﬁbroblasts. Quantiﬁcation of lipid peroxidation was reported as
broblasts. (E and F) Representative “in situ” SOD activity assay, determined by histo-
nds by densitometric analysis. Data are expressed as percentage of CTRL values (F).
and DS+EGCG, respectively). All data are reported as means (±SEM) of experiments
untreated and treated cells are indicated with asterisks (*=Pb0.01).
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factors considered essential for the expression of OXPHOS genes in
mammals: the mitochondrial transcription factor A (T-FAM), critical
for the regulation of mitochondrial gene transcription and DNA replica-
tion, and the nuclear respiratory factor 1 (NRF-1), which is a positive
regulator of T-FAM expression [37]. As shown in Fig. 5D and E, the
level of both NRF-1 and T-FAM proteins, slightly higher in DS cells as
compared with controls, further increased in EGCG-treated DS cells, in-
dicating that an activation of mitochondrial biogenesis pathway by
EGCG occurred. A slight but signiﬁcant increase of the protein levels of
these transcription factors was also found in EGCG-treated control cells.
We checked the morphology of mitochondria in EGCG-treated cells
by Transmission Electron Microscopy (Fig. 6). Ultrastructural inspection
of DS and control ﬁbroblasts revealed thatmitochondria, more abundant
in EGCG-treated cells (see Table in Fig. 6), did not presentmorphological
alterations or changes in sizewith respect to untreated cells. As a distinc-
tive feature, DS and control ﬁbroblasts showed an abundant rough endo-
plasmic reticulum (RER) characterized by expanded cisternae with aFig. 5. EGCG promotesmitochondrial biogenesis in human DS cells. (A) Immunoblotting analys
complex III (CIII), COX I of complex IV (CIV) and α subunit of F1 ATPase (CV) in untreated an
(0.05 mg protein); protein levels of porin and β-actin as mitochondrial and cytosolic protein
real-time PCR. Two mtDNA markers (D-loop and COX-2) were used. Values are the mean±S.
(B) ﬁbroblast and (C) lymphoblastoid cell lines. (D) Representative immunoblotting and (E) d
the mitochondrial transcription factor A (T-FAM) measured in lymphoblastoid cell extracts (
were treated for 24 h with 20 μM EGCG (CT+EGCG and DS+EGCG, respectively). Signiﬁcantroundish shape, studded with ribosomes. Interestingly, following EGCG
treatment, both DS and control cells showed an almost full contraction
of RER cisternae, which form large roundish shaped vesicles became
stretched-out tubuleswith a signiﬁcant reduction of organelle lumen. In-
terestingly, in EGCG treated cells, about 40% of total mitochondria
established a strict connection with RER tubule, which appeared to sur-
round mitochondria, a phenomenon only rarely observed in untreated
ﬁbroblasts.
3.5. EGCG promotes Sirt1 activity and PGC1α activation in human DS
cells
To investigate the molecular mechanism by which EGCG pro-
motes mitochondrial biogenesis, we measured the protein level of
the peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α,
the master regulator of mitochondrial biogenesis [38,39], of the cAMP
response element-binding (CREB) and phospho-CREB (P-CREB), which
promotes the expression of PGC-1α and of the NRF-1 transcriptionis of 20-kDa subunit of complex I (CI), 30-kDa subunit of complex II (CII), core 2 protein of
d treated normal (CT) and DS cells from both ﬁbroblast and lymphoblastoid cell extracts
markers, respectively, were also analyzed. (B and C) mtDNA content was assayed using
E. of three independent experiments on ﬁve normal (CT) and six DS cell lines from both
ensitometric analysis of protein levels of the nuclear respiratory factor 1 (NRF-1) and of
0.05 mg protein) using the respective antibodies. Where indicated, normal and DS cells
differences between groups are indicated with asterisks (*=Pb0.01).
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and can directly phosphorylate and activate CREB [42]. The amount of
DYRK1A and P-CREB proteins was found signiﬁcantly higher in DS as
compared with control cells (Fig. 7A and B). Although DYRK1A protein
level was not modiﬁed by EGCG treatment of DS cells, a signiﬁcant de-
creased phosphorylation of CREB was found in the EGCG-treated DS
cells in spite of no changes in CREB level. Interestingly, the level of
PGC-1α protein appeared to be lowered by EGCG treatment of DS cells.
These ﬁndings indicate that activation of the mitochondrial biogenesis
by EGCG does not occur through phosphorylation-dependent activation
of CREB or promotion of PGC-1α protein expression.
PGC-1α activity can, on the other hand, be modulated by post-
translational modiﬁcations. A key player in this respect is the NAD-
dependent deacetylase Sirt1 [38]. In spite of no signiﬁcant changes in
Sirt1 and Sirt3 protein levels in untreated and EGCG-treated DS cells
with respect to control cells (Fig. 7C and D), a signiﬁcant decrease of
acetylated histone 3 (AC-H3), a known downstream target of Sirt1
[43]was found in DS cells (approximately 2-foldwith respect to normal
cells) (Fig. 7E and F). Further decrease of AC-H3 was observed in
EGCG-treated DS cells (4-fold with respect to untreated DS cells), an in-
direct evidence of increased Sirt1 deacetylase activity. A signiﬁcant de-
crease of hystone acetylation was also found in EGCG-treated control
cells.
Consistently, analysis of the PGC-1α acetylation level showed
that PGC-1α acetylation was lower (about 2-fold) in the PGC-1α
immunoprecipitated from DS cells as compared with normal cells
(Fig. 7G and H). EGCG treatment resulted in further decrease in
PGC-1α acetylation both in control and in DS cells (about 3-fold
with respect to untreated DS cells) (Fig. 7H).
The dependence of sirtuin-mediated deacetylation onNAD+ links this
enzymatic activity to the energy status of the cell via the cellular NAD+:
NADH ratio. Compatible with the activation of sirtuin-dependent
deacetylation activity, a signiﬁcant increase in NAD+ levels, as well as
of the NAD+:NADH ratio, was observed in DS cells with respect to nor-
mal cells. NAD+ levels and NAD+:NADH ratiowere further enhanced in
EGCG-treated DS cells (Table 1).Fig. 6. Ultrastructural analysis of human DS and control ﬁbroblast cells following EGC4. Discussion
In the present study we tested whether and how EGCG can counter-
act mitochondrial energy deﬁcit and oxidative stress in DS cells. Our in-
vestigation was based on the critical role of mitochondrial dysfunction
in the pathogenesis of DS [6–9] and the distinctive features of EGCG
as: i) a mitochondria-targeted drug [14,15], ii) a powerful antioxidant
and modulator of cell signaling pathways (for Refs. see [18]), iii) an in-
hibitor of the chromosome 21-encoded DYRK1A, able to rescue brain
defects induced by DYRK1A overexpression [22,24], iv) a molecule
which can pass through both the blood–brain and feto-maternal pla-
cental barriers without side effects in humans [44–46]. EGCG was
used in this study at a concentration of 20 μM, which we directly veri-
ﬁed to be safe for the cells being neither pro-oxidant nor cytotoxic
even after prolonged exposure.
Cells with chromosome 21 trisomy, obtained from tissues of patients
at different development stages, fetal ﬁbroblasts and lymphoblastoids
established from children, as well as ﬁbroblasts from adults with DS, all
show comparable mitochondrial alterations [see also 8,9]. This allows us
to argue that dysfunction of mitochondrial bioenergetics in these cells is
an inherent feature of DS and that designing drugs that canmodulatemi-
tochondrial functions is an attractive strategy for therapeutic gain [47].
It is shown here that the deﬁcit of complex I and ATP synthase ac-
tivities in DS cells results in depression of the rate of mitochondrial
ATP synthesis, as well as in a marked depression of the cellular ATP
content in a galactose cultivation medium, a condition in which ATP
is essentially produced by mitochondrial OXPHOS. The present results
show for the ﬁrst time that EGCG treatment renews the capacity of DS
cells to produce energy by mitochondrial OXPHOS by restoring the
impaired activities of complex I and ATP synthase and the overall
rate of mitochondrial ATP synthesis.
There is general consensus that a disturbance in the balance of ROS
might play a crucial role in DS pathogenesis; a misbalance between the
chromosome 21-encoded Cu/ZnSOD and glutathione peroxidase activity
is believed to underlie the increased oxidative stress in DS [48].We previ-
ously indicatedmitochondria as themajor cellular site responsible for theG treatment. Rough endoplasmic reticulum: rer; mitochondrion: m; nucleus: N.
Fig. 7. EGCG modulates the Sir1/PGC1α signaling pathway. (A) Representative immunoblotting and (B) densitometric analysis of protein levels of PGC-1α, P-CREB, CREB and
DRK1A, measured in CT, DS and DS+EGCG lymphoblastoid cell extracts (0.05 mg protein) using the respective antibodies. (C) Representative immunoblotting and (D) densitomet-
ric analysis of protein levels of Sirt1 and Sirt3. (E) Representative immunoblotting and (F) densitometric analysis of acetylated histone 3 (AC-H3) and nonacetylated histone 3 (H3)
measured in CT and DS untreated and EGCG-treated lymphoblastoid cell extracts. The levels of histone acetylation are calculated as ratio of AC-H3/H3. (G) Representative immu-
noblotting analysis and (H) densitometric analysis of acetylated-lysine of immunoprecipitated PGC-1α from CT and DS untreated and EGCG-treated lymphoblastoid cells. The levels
of PGC-1α acetylation are calculated as ratio of acetylated-lysine vs immunoprecipitated PGC-1α. Values are the mean (±S.E.) of three independent experiments on ﬁve normal
and six DS samples from lymphoblastoid cell lines. Signiﬁcant among groups are indicated with asterisks (*=pb0.01).
Table 1
Changes in pyridine nucleotide metabolism in DS cells and after treatment with EGCG.
CT DS DS+EGCG
NAD+ (nmol/mg prot.) 1.3±0.2 2.7*±0.2 4.4*±0.2
NADH (nmol/mg prot.) 0.22±0.06 0.32±0.05 0.37±0.07
NAD+/NADH 5.9±0.5 8.4*±0.4 11.9*±0.6
NAD+ and NADH content were determined in both DS and control (CT) lymphoblastoid
cells, incubated in the absence or in the presence of 20 μM EGCG for 24 h, using NAD/
NADH Assay Kit from Abcam. All values are means±S.E of three different measurements
on six DS and ﬁve CT cell lines. Signiﬁcant differences between groups are indicated with
asterisks (*=pb0.01).
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counteracts oxidative stress, not acting on theROS scavenging enzyme ac-
tivities, but preventing mitochondrial ROS overproduction by rescuing
the efﬁciency of OXPHOS, in particular of complex I.
Alterations in the post-translational cAMP/PKA-mediated regulation
of the catalytic activity of mitochondrial proteins involved in oxidative
phosphorylation are involved in mitochondrial energy deﬁcit in DS
cells [8,9]. Given that EGCG has been found to be a powerful inhibitor
of the activity of the cyclic nucleotide phosphodiesterase [20] and an ac-
tivator of adenylyl cyclase [21], we tested the effect of EGCG on cAMP/
PKA signaling pathway in DS cells. Our results show that EGCG
551D. Valenti et al. / Biochimica et Biophysica Acta 1832 (2013) 542–552promotes in DS cells an increase of cAMP levels and PKA activity with
respect to untreated cells, which results in increase in NDUFS4 phos-
phorylation, a subunit of complex I, and hence in complex I activation.
An effective strategy helping to minimize a damage attributable to
mitochondrial energy impairment, is to increase the OXPHOS capacity
and the number of mitochondria [49]. As known, mitochondrial bio-
genesis involves the integration of multiple transcriptional pathways
controlling both nuclear and mitochondrial gene expression. The
transcription factor NRF-1 plays a key role in integrating the tran-
scription of nuclear- and mitochondrial-encoded genes [34]. NRF-1
target genes include subunits of OXPHOS complexes, assembly factors
for the respiratory apparatus, components of mitochondrial protein
import, and key mtDNA replication and transcription factors such as
T-FAM [50]. The expression of NRF-1 is promoted by the coactivator
PGC-1α [39]. Increase of PGC-1α activity, effected at both the expres-
sion and post-translational levels, results in increased mitochondrial
mass and overall mitochondrial function [38]. In DS cells, as expected,
we found an increase (about 50% with respect to normal cells) in the
protein level of the chromosome 21 encoded DYRK1A, a protein ki-
nase involved in several signal transduction pathways (for Refs. see
[51]). It is known that DYRK1A phosphorylates and activates both
CREB and Sirt1 in different cell types [42,52]. Consistently, the pres-
ent results show an increase of P-CREB protein level and, interesting-
ly, of sirtuin-dependent hystone deacetylation activity and PGC-1α
deacetylation in DS cells under basal conditions. This could account
for the increased mitochondrial biogenesis of DS cells, to partially
compensate the mitochondrial energy deﬁcit.
Recent studies have shown that exogenously supplied factors may
be able to drive mitochondrial biogenesis by augmenting endogenous
signaling responses [40,53]. The present study shows that in DS cells
EGCG upregulates NRF-1 and T-FAM and strongly increases the level
of OXPHOS proteins and mtDNA copy number. This promoting effect
exerted by EGCG did not involve up-stream stimulation of CREB phos-
phorylation neither expression of PGC-1α which were instead both
depressed by EGCG. In addition, EGCG treatment in DS cells, although
does not affect DYRK1A expression, as shown in a mouse model of DS
[24], affects the activity of DYRK1A decreasing the phosphorylation of
CREB, a downstream DYRK1A target. On the other hand, EGCG did in-
duce a further increase of the hystone deacetylation activity and
PGC-1α deacetylation in both DS and control cells. These results indi-
cate that the EGCG inducing increase of NRF-1, T-FAM and OXPHOS
proteins in DS cells can be due to sirtuin-catalyzed post-translational
deacetylation of PGC-1α and consequent promotion of its down-stream
co-transcriptional activity.
The observed increase of cellular NAD+ levels induced by EGCG in
DS cells, probably due to a stimulation of NAD+ biosynthesis [54], can
be involved in the activation of sirtuin(s).
These ﬁndings are consistent with reports showing that polyphe-
nols, like resveratrol and EGCGmodulate Sirt1 activity [19,43]. Sirt1 ac-
tivation can also occur through PKA-mediated phosphorylation [55].
Further work is in progress to verify whether the EGCG-dependent
PKA activation correlates with promotion of Sirt1 activity.
It is interesting to note that, at ultrastructural level, EGCG treat-
ment induces considerable changes in RER structure and organization
and that several RER-mitochondria interconnection can be observed.
As RER-mitochondria connections are directly involved in the regula-
tion of mitochondrial membrane biosynthesis, genome replication,
Ca2+ signaling and protein import [56,57] our data further indicate
that EGCG protects DS cells ameliorating their mitochondrial biology.
It is interesting to note that the same structural reorganization occurs
also in normal cells substantiating the positive effects of this green tea
extract on cell metabolism.
In conclusion, the present report gives new indication on molecu-
lar mechanisms occurring in DS cells leading to compensative events
towards the energy deﬁcit and identiﬁes a novel activity of EGCG to
counteract mitochondrial energy deﬁcit in DS. In particular, EGCG,stimulating both cAMP/PKA and Sirt1/PGC1α signaling pathways, is
able to restore oxidative phosphorylation capacity and promote mito-
chondrial biogenesis in ﬁbroblast and lymphoblastoid cells obtained
from DS subject. These ﬁndings provide a useful background for in
vivo studies and suggest that EGCG, through the promoting effect
on mitochondrial bioenergetic functions in DS cells, could contribute
to the therapeutic treatment of this disease.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.12.011.
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